Medical treatment of uterine leiomyoma

Mohamed Sabry, Ayman Al-Hendy

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Uterine leiomyomas (also called myomata or fibroids) are the most common gynecologic tumors in the United States. The prevalence of leiomyomas is at least 3 to 4 times higher among African American women than in white women. Pathologically, uterine leiomyomas are benign tumors that arise in any part of the uterus under the influence of local growth factors and sex hormones, such as estrogen and progesterone. These common tumors cause significant morbidity for women and they are considered to be the most common indication for hysterectomy in the world; they are also associated with a substantial economic impact on health care systems that amounts to approximately $2.2 billion/year in the United States alone. Uterine myomas cause several reproductive problems such as heavy or abnormal uterine bleeding, pelvic pressure, infertility, and several obstetrical complications including miscarriage and preterm labor. Surgery has traditionally been the gold standard for the treatment of uterine leiomyomas and has typically consisted of either hysterectomy or myomectomy. In recent years, a few clinical trials have evaluated the efficacy of orally administered medications for the management of leiomyoma-related symptoms. In the present review, we will discuss these promising medical treatments in further detail.

Original languageEnglish (US)
Pages (from-to)339-353
Number of pages15
JournalReproductive Sciences
Volume19
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Leiomyoma
Myoma
Hysterectomy
Uterine Myomectomy
Therapeutics
Neoplasms
Uterine Hemorrhage
Premature Obstetric Labor
Gonadal Steroid Hormones
Spontaneous Abortion
African Americans
Infertility
Growth Hormone
Uterus
Progesterone
Intercellular Signaling Peptides and Proteins
Estrogens
Economics
Clinical Trials
Morbidity

Keywords

  • fibroid
  • leiomyoma
  • medical
  • myoma
  • nonsurgical treatment

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Medical treatment of uterine leiomyoma. / Sabry, Mohamed; Al-Hendy, Ayman.

In: Reproductive Sciences, Vol. 19, No. 4, 01.04.2012, p. 339-353.

Research output: Contribution to journalReview article

Sabry, Mohamed ; Al-Hendy, Ayman. / Medical treatment of uterine leiomyoma. In: Reproductive Sciences. 2012 ; Vol. 19, No. 4. pp. 339-353.
@article{8b864718bc2e4c178e7e97d760f997ba,
title = "Medical treatment of uterine leiomyoma",
abstract = "Uterine leiomyomas (also called myomata or fibroids) are the most common gynecologic tumors in the United States. The prevalence of leiomyomas is at least 3 to 4 times higher among African American women than in white women. Pathologically, uterine leiomyomas are benign tumors that arise in any part of the uterus under the influence of local growth factors and sex hormones, such as estrogen and progesterone. These common tumors cause significant morbidity for women and they are considered to be the most common indication for hysterectomy in the world; they are also associated with a substantial economic impact on health care systems that amounts to approximately $2.2 billion/year in the United States alone. Uterine myomas cause several reproductive problems such as heavy or abnormal uterine bleeding, pelvic pressure, infertility, and several obstetrical complications including miscarriage and preterm labor. Surgery has traditionally been the gold standard for the treatment of uterine leiomyomas and has typically consisted of either hysterectomy or myomectomy. In recent years, a few clinical trials have evaluated the efficacy of orally administered medications for the management of leiomyoma-related symptoms. In the present review, we will discuss these promising medical treatments in further detail.",
keywords = "fibroid, leiomyoma, medical, myoma, nonsurgical treatment",
author = "Mohamed Sabry and Ayman Al-Hendy",
year = "2012",
month = "4",
day = "1",
doi = "10.1177/1933719111432867",
language = "English (US)",
volume = "19",
pages = "339--353",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Medical treatment of uterine leiomyoma

AU - Sabry, Mohamed

AU - Al-Hendy, Ayman

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Uterine leiomyomas (also called myomata or fibroids) are the most common gynecologic tumors in the United States. The prevalence of leiomyomas is at least 3 to 4 times higher among African American women than in white women. Pathologically, uterine leiomyomas are benign tumors that arise in any part of the uterus under the influence of local growth factors and sex hormones, such as estrogen and progesterone. These common tumors cause significant morbidity for women and they are considered to be the most common indication for hysterectomy in the world; they are also associated with a substantial economic impact on health care systems that amounts to approximately $2.2 billion/year in the United States alone. Uterine myomas cause several reproductive problems such as heavy or abnormal uterine bleeding, pelvic pressure, infertility, and several obstetrical complications including miscarriage and preterm labor. Surgery has traditionally been the gold standard for the treatment of uterine leiomyomas and has typically consisted of either hysterectomy or myomectomy. In recent years, a few clinical trials have evaluated the efficacy of orally administered medications for the management of leiomyoma-related symptoms. In the present review, we will discuss these promising medical treatments in further detail.

AB - Uterine leiomyomas (also called myomata or fibroids) are the most common gynecologic tumors in the United States. The prevalence of leiomyomas is at least 3 to 4 times higher among African American women than in white women. Pathologically, uterine leiomyomas are benign tumors that arise in any part of the uterus under the influence of local growth factors and sex hormones, such as estrogen and progesterone. These common tumors cause significant morbidity for women and they are considered to be the most common indication for hysterectomy in the world; they are also associated with a substantial economic impact on health care systems that amounts to approximately $2.2 billion/year in the United States alone. Uterine myomas cause several reproductive problems such as heavy or abnormal uterine bleeding, pelvic pressure, infertility, and several obstetrical complications including miscarriage and preterm labor. Surgery has traditionally been the gold standard for the treatment of uterine leiomyomas and has typically consisted of either hysterectomy or myomectomy. In recent years, a few clinical trials have evaluated the efficacy of orally administered medications for the management of leiomyoma-related symptoms. In the present review, we will discuss these promising medical treatments in further detail.

KW - fibroid

KW - leiomyoma

KW - medical

KW - myoma

KW - nonsurgical treatment

UR - http://www.scopus.com/inward/record.url?scp=84859905006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859905006&partnerID=8YFLogxK

U2 - 10.1177/1933719111432867

DO - 10.1177/1933719111432867

M3 - Review article

C2 - 22378865

AN - SCOPUS:84859905006

VL - 19

SP - 339

EP - 353

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 4

ER -